8
Participants
Start Date
June 17, 2010
Primary Completion Date
January 6, 2012
Study Completion Date
January 6, 2012
methadone hydrochloride
"Level 1: 1 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA\*\* per day)~Level 2: 2 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~Level 3: 3mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~OR~Level 1: 2 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~Level 2: 3 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~Level 3: 4 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)"
questionnaire administration
within 48 hours of registration
management of therapy complications
if required
Cross Cancer Institute, Edmonton
BCCA - Cancer Centre for the Southern Interior, Kelowna
BCCA - Vancouver Cancer Centre, Vancouver
CancerCare Manitoba, Winnipeg
Cancer Centre of Southeastern Ontario at Kingston, Kingston
Univ. Health Network-Princess Margaret Hospital, Toronto
McGill University - Dept. Oncology, Montreal
Lead Sponsor
NCIC Clinical Trials Group
NETWORK